What is the share price of Lupin Ltd (LUPIN) today?
The share price of LUPIN as on 4th July 2025 is ₹1980.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Lupin Ltd (LUPIN) share?
The past returns of Lupin Ltd (LUPIN) share are- Past 1 week: 0.87%
- Past 1 month: -0.11%
- Past 3 months: 0.50%
- Past 6 months: -16.07%
- Past 1 year: 12.60%
- Past 3 years: 215.28%
- Past 5 years: 126.25%
What are the peers or stocks similar to Lupin Ltd (LUPIN)?
The peers or stocks similar to Lupin Ltd (LUPIN) include:What is the dividend yield % of Lupin Ltd (LUPIN) share?
The current dividend yield of Lupin Ltd (LUPIN) is 0.60.What is the market cap of Lupin Ltd (LUPIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd (LUPIN) is ₹90470.90 Cr as of 4th July 2025.What is the 52 week high and low of Lupin Ltd (LUPIN) share?
The 52-week high of Lupin Ltd (LUPIN) is ₹2402.90 and the 52-week low is ₹1651.15.What is the PE and PB ratio of Lupin Ltd (LUPIN) stock?
The P/E (price-to-earnings) ratio of Lupin Ltd (LUPIN) is 27.57. The P/B (price-to-book) ratio is 6.29.Which sector does Lupin Ltd (LUPIN) belong to?
Lupin Ltd (LUPIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Lupin Ltd (LUPIN) shares?
You can directly buy Lupin Ltd (LUPIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Lupin Ltd
LUPIN Share Price
LUPIN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LUPIN Performance & Key Metrics
LUPIN Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
27.57 | 6.29 | 0.60% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.15 | 6.59 | 0.82% |
from 34 analysts
Price Upside
Earnings Growth
Rev. Growth
LUPIN Company Profile
Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
LUPIN Sentiment Analysis
LUPIN Sentiment Analysis
LUPIN Stock Summary · May 2025
The company has demonstrated robust financial performance, achieving USD 2.7 billion in revenue and a significant EBITDA margin of 23.7%, driven by strategic growth in complex generics and biosimilars. With a strong product pipeline and recent launches, particularly in the U.S. market, it is well-positioned to capitalize on emerging opportunities, despite facing challenges from increased competition and regulatory dynamics. Operational efficiencies are being prioritized, with investments in R&D and manufacturing capabilities enhancing its competitive edge. Additionally, the focus on expanding into tier two and three markets, alongside a commitment to sustainability and compliance, underscores a proactive approach to long-term growth and market resilience. Overall, the outlook remains optimistic, with expectations for sustained double-digit growth supported by strategic initiatives and a diversified portfolio.
LUPIN Stock Growth Drivers
LUPIN Stock Growth Drivers
8Strong Financial Performance
The company has reported significant financial achievements, including USD 2.7 billion in revenue and USD
Successful Product Launches
The company has successfully launched several key products, including Mirabegron, Spiriva®, and Tolvaptan, contributing to
LUPIN Stock Challenges
LUPIN Stock Challenges
3Impact of Regulatory Changes on Pharmaceutical Innovation
The U.S. healthcare landscape is facing significant challenges due to regulatory changes, particularly the Most
Challenges in Financial Performance and Margin Pressure
The company is experiencing negative impacts on its core EBITDA margin, which currently stands at
LUPIN Forecast
LUPIN Forecasts
Price
Revenue
Earnings
LUPIN Share Price Forecast
LUPIN Share Price Forecast
All values in ₹
All values in ₹
LUPIN Company Revenue Forecast
LUPIN Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
LUPIN Stock EPS (Earnings Per Share) Forecast
LUPIN Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
LUPIN
LUPIN
Income
Balance Sheet
Cash Flow
LUPIN Income Statement
LUPIN Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 17,482.14 | 15,950.42 | 15,095.78 | 15,992.56 | 15,300.58 | 16,615.93 | 16,792.57 | 20,141.50 | 22,903.72 | 22,928.63 | ||||||||||
Raw Materials | 5,339.31 | 5,111.62 | 5,150.54 | 5,422.05 | 5,847.10 | 6,679.56 | 6,626.03 | 7,100.91 | 17,424.59 | 17,449.50 | ||||||||||
Power & Fuel Cost | 377.86 | 433.88 | 442.28 | 443.17 | 414.48 | 443.96 | 479.68 | 493.07 | ||||||||||||
Employee Cost | 2,849.52 | 2,864.71 | 2,770.17 | 2,986.84 | 2,825.90 | 2,989.30 | 3,087.15 | 3,494.57 | ||||||||||||
Selling & Administrative Expenses | 2,377.17 | 2,386.87 | 2,513.07 | 2,541.16 | 2,230.63 | 2,490.56 | 2,755.54 | 3,350.98 | ||||||||||||
Operating & Other expenses | 1,930.38 | 3,316.31 | 1,567.76 | 2,378.81 | 1,277.97 | 3,583.28 | 1,972.69 | 1,771.28 | ||||||||||||
EBITDA | 4,607.90 | 1,837.03 | 2,651.96 | 2,220.53 | 2,704.50 | 429.27 | 1,871.48 | 3,930.69 | 5,479.13 | 5,479.13 | ||||||||||
Depreciation/Amortization | 912.23 | 1,085.87 | 846.05 | 970.22 | 887.41 | 1,658.71 | 880.69 | 1,196.81 | 1,169.26 | 1,169.26 | ||||||||||
PBIT | 3,695.67 | 751.16 | 1,805.91 | 1,250.31 | 1,817.09 | -1,229.44 | 990.79 | 2,733.88 | 4,309.87 | 4,309.87 | ||||||||||
Interest & Other Items | 152.53 | 204.35 | 302.49 | 362.98 | 140.64 | 142.77 | 274.30 | 311.61 | 294.87 | 294.87 | ||||||||||
PBT | 3,543.14 | 546.81 | 1,503.42 | 887.33 | 1,676.45 | -1,372.21 | 716.49 | 2,422.27 | 4,015.00 | 4,015.00 | ||||||||||
Taxes & Other Items | 985.68 | 295.55 | 896.87 | 1,156.72 | 459.92 | 155.83 | 286.41 | 507.79 | 733.38 | 733.38 | ||||||||||
Net Income | 2,557.46 | 251.26 | 606.55 | -269.39 | 1,216.53 | -1,528.04 | 430.08 | 1,914.48 | 3,281.62 | 3,281.62 | ||||||||||
EPS | 56.70 | 5.56 | 13.41 | -5.95 | 26.83 | -33.65 | 9.46 | 42.05 | 71.95 | 72.02 | ||||||||||
DPS | 7.50 | 5.00 | 5.00 | 6.00 | 6.50 | 4.00 | 4.00 | 8.00 | 12.00 | 8.00 | ||||||||||
Payout ratio | 0.13 | 0.90 | 0.37 | — | 0.24 | — | 0.42 | 0.19 | 0.17 | 0.11 |
LUPIN Company Updates
Investor Presentation
LUPIN Stock Peers
LUPIN Past Performance & Peer Comparison
LUPIN Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Lupin Ltd | 27.57 | 6.29 | 0.60% |
Sun Pharmaceutical Industries Ltd | 36.80 | 5.99 | 0.95% |
Cipla Ltd | 23.18 | 3.91 | 1.06% |
Torrent Pharmaceuticals Ltd | 59.65 | 16.63 | 0.95% |
LUPIN Stock Price Comparison
Compare LUPIN with any stock or ETFLUPIN Holdings
LUPIN Shareholdings
LUPIN Promoter Holdings Trend
LUPIN Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
LUPIN Institutional Holdings Trend
LUPIN Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
LUPIN Shareholding Pattern
LUPIN Shareholding Pattern
LUPIN Shareholding History
LUPIN Shareholding History
Mutual Funds Invested in LUPIN
Mutual Funds Invested in LUPIN
No mutual funds holding trends are available
Top 5 Mutual Funds holding Lupin Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2184% | Percentage of the fund’s portfolio invested in the stock 1.10% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/325 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7290% | Percentage of the fund’s portfolio invested in the stock 1.75% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/49 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6620% | Percentage of the fund’s portfolio invested in the stock 1.52% | Change in the portfolio weight of the stock over the last 3 months 0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/113 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing LUPIN stock
smallcases containing LUPIN stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Lupin Ltd
LUPIN Events
LUPIN Events
LUPIN Dividend Trend
Current dividend yield is 0.60%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.04 every year
Dividends
Corp. Actions
Announcements
Legal Orders
LUPIN Dividend Trend
Current dividend yield is 0.60%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.04 every year
LUPIN Upcoming Dividends
LUPIN Upcoming Dividends
No upcoming dividends are available
LUPIN Past Dividends
LUPIN Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹8.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJul 27, 2021
Dividend/Share
₹6.50
Ex DateEx Date
Jul 27, 2021
Cash Dividend
Ex DateEx DateAug 3, 2020
Dividend/Share
₹6.00
Ex DateEx Date
Aug 3, 2020
LUPIN Stock News & Opinions
LUPIN Stock News & Opinions
Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent' Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent') had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live
Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today. Powered by Capital Market - Live
The product is a generic equivalent of Lotemax SM Ophthalmic Gel, 0.38%, marketed by Bausch & Lomb Inc. Lupin is the exclusive first-to-file applicant for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax' SM) had estimated annual sales of $29 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.85% to Rs 1,978.05 on the BSE.Powered by Capital Market - Live
Lupin announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare (LCH), into a wholly owned subsidiary, effective 01 July 2025. This initiative aligns with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing self care market. Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac', Beplex Forte', Corcium' and Aptivate'. Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth. Powered by Capital Market - Live
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. Loteprednol Etabonate Ophthalmic Gel, 0.38% is bioequivalent to Lotemax' SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax' SM) had an estimated annual sale of USD 29 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live
Lupin has today, 30 June 2025, executed a Business Transfer Agreement (BTA) for transfer of its Over-the-Counter Consumer Healthcare Business (OTC Business) to LUPINLIFE Consumer Healthcare (LCHL), a wholly owned subsidiary of the Company, on a slump sale basis. In terms of the BTA, the said transaction has been completed, and transfer of OTC Business will be effective from 01 July 2025.Powered by Capital Market - Live
Prucalopride Tablets are the bioequivalent of Motegrity' Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc. The medication is indicated for the treatment of chronic idiopathic constipation (CIC) in adult patients. According to IQVIA MAT data for April 2025, the reference drug Motegrity' recorded annual sales of approximately $184 million in the U.S. market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.11% to Rs 1,913.70 on the BSE. Powered by Capital Market - Live
Lupin'announced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Prucalopride Tablets are bioequivalent to Motegrity' Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity') had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025). Powered by Capital Market - Live
The tablets are a generic equivalent of Motegrity' Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc., and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Lupin stated that the approved product is bioequivalent to Motegrity' and will be manufactured at the company's facility in Goa, India. According to IQVIA MAT data for April 2025, Prucalopride Tablets (Reference Listed Drug: Motegrity') had estimated annual sales of approximately $184 million in the United States. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.07% to Rs 1,932.10 on the BSE. Powered by Capital Market - Live
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg, and 2 mg. Prucalopride Tablets are bioequivalent to Motegrity' Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. This product will be manufactured at Lupin's Goa facility in India. Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity') had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025). Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 7.45%, vs industry avg of 10.14%
Over the last 5 years, market share decreased from 6.37% to 5.55%